RxDoctor Payments DataLook up a doctor →

Chad Stuckey, MD

Neurology · Oklahoma City, OKNPI 1275715880

Payments from drug & device makers

$5,497in general payments, 2019–2025

Across 331 payments — averaging $16.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Supernus Pharmaceuticals, Inc.$396
  • UCB, Inc.$262
  • Neurocrine Biosciences, Inc.$255
  • Novartis$247
  • AstraZeneca$228
  • plus $3K from 39 others

What the payments were for

  • Speaking & faculty fees$391%
  • Food & beverage$5,44699%
  • Education$120%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,497 in reported general payments places this provider in the 60th percentile of 152 neurology providers in Oklahoma.

See all neurology providers in Oklahoma

Medicare billing

Part B allowed, 2024
$200,978
Medicare patients
666
Services billed
4,993

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Aimovig AutoinjectorErenumab-Aooe77$60,722
NuplazidPimavanserin Tartrate14$58,482
Nurtec OdtRimegepant Sulfate27$51,907
BriviactBrivaracetam14$41,699
Emgality PenGalcanezumab-Gnlm33$27,214
Dimethyl Fumarate11$22,111
UbrelvyUbrogepant16$21,617
BotoxOnabotulinumtoxina11$19,818
RytaryCarbidopa/Levodopa16$18,888
Lacosamide82$14,284
Memantine Hcl534$12,747
Donepezil Hcl553$9,462
Levetiracetam172$6,585
Carbidopa-LevodopaCarbidopa/Levodopa247$5,123
ViibrydVilazodone Hcl11$4,352

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Acadia Pharmaceuticals IncNuplazid$172$58,48214 claims
PfizerNurtec Odt$133$51,90727 claims
AbbVieUbrelvy, Botox, Viibryd$1,403$45,78638 claims
UCB, Inc.Briviact$262$41,69914 claims
Amneal Pharmaceuticals LLCRytary$105$18,88816 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 152 neurology providers in Oklahoma.

Other neurology in Oklahoma City

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →